Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test
Copyright © 2022. Published by Elsevier B.V..
BACKGROUND: We investigated the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, on a depression-like phenotype in mice exposed to chronic unpredictable stress (CUS). Learning and memory were also assessed using the Morris water maze (MWM) test.
METHODS: Liraglutide (0.3 mg/kg/day for 21 days) was administered to mice with or without exposure to CUS. After 21 days of CUS, the forced swim test (FST) was performed to assess its antidepressant effect. To evaluate cognitive function, liraglutide was administered to mice under stress-free conditions for 21 days, and then the MWM test was performed on 6 consecutive days.
RESULTS: Chronic liraglutide treatment reduced FST immobility in mice with and without CUS. In the probe trial of the Morris water maze test, the search error rate was reduced and the time spent and path length in the target quadrant and the number of platform crossings were increased.
LIMITATION: Additional animal model experiments and molecular level studies are needed to support the results obtained in this study.
CONCLUSIONS: Liraglutide appears to exert antidepressant effects and could improve cognitive function. Based on these results, GLP-1 agonists could have potential as novel antidepressants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:324 |
|---|---|
| Enthalten in: |
Journal of affective disorders - 324(2023) vom: 01. März, Seite 8-15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seo, Mi Kyoung [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.01.2023 Date Revised 17.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jad.2022.12.089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350784272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350784272 | ||
| 003 | DE-627 | ||
| 005 | 20231226045800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jad.2022.12.089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350784272 | ||
| 035 | |a (NLM)36566932 | ||
| 035 | |a (PII)S0165-0327(22)01449-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seo, Mi Kyoung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2023 | ||
| 500 | |a Date Revised 17.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: We investigated the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, on a depression-like phenotype in mice exposed to chronic unpredictable stress (CUS). Learning and memory were also assessed using the Morris water maze (MWM) test | ||
| 520 | |a METHODS: Liraglutide (0.3 mg/kg/day for 21 days) was administered to mice with or without exposure to CUS. After 21 days of CUS, the forced swim test (FST) was performed to assess its antidepressant effect. To evaluate cognitive function, liraglutide was administered to mice under stress-free conditions for 21 days, and then the MWM test was performed on 6 consecutive days | ||
| 520 | |a RESULTS: Chronic liraglutide treatment reduced FST immobility in mice with and without CUS. In the probe trial of the Morris water maze test, the search error rate was reduced and the time spent and path length in the target quadrant and the number of platform crossings were increased | ||
| 520 | |a LIMITATION: Additional animal model experiments and molecular level studies are needed to support the results obtained in this study | ||
| 520 | |a CONCLUSIONS: Liraglutide appears to exert antidepressant effects and could improve cognitive function. Based on these results, GLP-1 agonists could have potential as novel antidepressants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antidepressant effect | |
| 650 | 4 | |a Chronic unpredictable stress | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a GLP-1 agonist | |
| 650 | 4 | |a Liraglutide | |
| 650 | 4 | |a Morris water maze | |
| 650 | 7 | |a Liraglutide |2 NLM | |
| 650 | 7 | |a 839I73S42A |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 700 | 1 | |a Jeong, Sehoon |e verfasserin |4 aut | |
| 700 | 1 | |a Seog, Dae-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jung An |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae-Hon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yena |e verfasserin |4 aut | |
| 700 | 1 | |a McIntyre, Roger S |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sung Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jung Goo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of affective disorders |d 1989 |g 324(2023) vom: 01. März, Seite 8-15 |w (DE-627)NLM000465615 |x 1573-2517 |7 nnns |
| 773 | 1 | 8 | |g volume:324 |g year:2023 |g day:01 |g month:03 |g pages:8-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jad.2022.12.089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 324 |j 2023 |b 01 |c 03 |h 8-15 | ||